On Friday, Shares of Corning Incorporated (NYSE:GLW), lost -0.53% to $18.00.
Corning Incorporated, declared that the Ford GT supercar is the first production vehicle to use Corning® Gorilla® Glass for Automotive in a windshield. Ford is also using the lightweight, tough and optically advantaged glass for two other applications within the car, saving more than 12 pounds of vehicle weight.
The innovative Ford GT windshield - a collaborative effort between Ford and Corning - comprises three layers: Gorilla Glass for Automotive as the inner layer, a plastic adhesive interlayer, and annealed soda lime glass as the outside layer.
Pound for pound, Gorilla Glass for Automotive can achieve more than five times the strength of standard window glass. This strength assists protect the windshield and make it thinner and lighter, while also providing outstanding optical advantages.
Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials worldwide. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences.
Shares of BP plc (ADR) (NYSE:BP), declined -0.63% to $30.16, during its last trading session.
Rio de Janeiro , March 31, 2015 - PetroRio (current brand of HRT Participações em Petróleo S.A. - “HRT”, “HRTP” or “Company” (BM&FBovespa: HRTP3 and TSX-V: HRP.V) declares its results for the fourth quarter of 2014 (“4Q14”). The financial and operational information below, except if otherwise indicated, is presented on a merged basis and stated in thousands of Brazilian Reais (R$) according to the International Financial Reporting Standards (IFRS), counting our direct auxiliaries: HRT O&G Exploração e Produção de Petróleo Ltda., HRT Africa Petróleo S.A., HRT America Inc. and their respective auxiliaries and branches.
BP p.l.c. operates as an integrated oil and gas company worldwide. It operates in three segments: Upstream, Downstream, and Rosneft. The Upstream segment engages in the oil and natural gas exploration, field development, and production; midstream transportation, and storage and processing; and marketing and trade of natural gas, counting liquefied natural gas (LNG), and power and natural gas liquids (NGL).
Finally, Advaxis, Inc. (NASDAQ:ADXS), ended its last trade with -3.25% loss, and closed at $11.92.
Advaxis, declared that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac (formerly ADXS-HPV), ADXS-PSA and ADXS-HER2. Advaxis will therefore resume all clinical trials with axalimogene filolisbac, ADXS-PSA and ADXS-HER2.
“We appreciate the FDA’s review of this matter. We are grateful that our clinical trials will now resume so that we may continue investigating new treatments for unmet medical needs. We thank both the patients and their physicians for their participation in our clinical trials,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis.
In October of 2015, Advaxis received notification from the FDA that its IND applications for axalimogene filolisbac were put on clinical hold in response to the company’s submission of a safety report to the FDA. The clinical hold also comprised the INDs for ADXS-PSA and ADXS-HER2. Following negotiations with the FDA and in accordance with their recommendations, the company agreed to implement certain risk mitigation measures, counting revised study protocol inclusion / exclusion criteria, post-administration antibiotic treatment and patient surveillance and monitoring measures.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.